Episode Summary
Dr. Lucy McBride sits down with Dr. Lauren Streicher, Northwestern University professor and sexual medicine expert, to untangle two decades of fear-based messaging about hormone therapy in the wake of the Women’s Health Initiative. They revisit what the WHI actually showed (and didn’t show) and make the case for individualized, evidence-based menopause care across hot flashes, sleep, bone health, genitourinary symptoms, and sexual health.
The WHI: A High-Quality Study That Was Badly Misread
The WHI was the first randomized controlled trial on menopausal women and hormone therapy — well-designed, but its early termination generated fear-based messaging clinicians are still undoing
The women who took estrogen only showed a reduced risk of breast cancer; the combined arm showed an increase of one case per thousand women, with breast cancer mortality still reduced
Hot Flashes Are Not Harmless
The average duration of hot flashes is seven years — 10 years in Black women, lifelong for 10%
Each hot flash triggers a spike in heart rate, blood pressure, cortisol, and inflammation that accumulates real cardiovascular damage over time
Chronic sleep disruption from menopause compounds that cardiovascular risk significantly
Local Vaginal Estrogen: Safe and Woefully Underused
Genitourinary syndrome of menopause — urgency, recurrent UTIs, pain with intercourse, pelvic floor dysfunction — is treatable at any age, including in women on aromatase inhibitors
The FDA recently removed the black box warning from vaginal estrogen; it was never warranted and existed only due to blanket class labeling tied to oral estrogens (listen to more discussion about the removal of the FDA black box warning here)
The 10-Year Window Is Not a Stop Sign
Women who start hormone therapy within 10 years of their last period tend to do better at a population level — it does not mean therapy must stop after 10 years
A woman still symptomatic at 62 is a very different conversation than a symptom-free woman who feels she missed the boat (read about options you may have after the 10 year window here)
Hormone Therapy and Breast Cancer: What the Science Actually Shows
For women with BRCA mutations, multiple studies — including a large 2025 prospective analysis — show no increased breast cancer risk on hormone therapy after oophorectomy. Breast cancer incidence was actually significantly lower in HRT users, with the protective effect concentrated in estrogen-only formulations.
For women with a prior breast cancer diagnosis, the evidence on HRT risk is limited and formulation-specific: older trials showed increased recurrence risk with combined estrogen-progestin (particularly in ER+ disease), but modern formulations are understudied, vaginal estrogen appears safe, and a 2025 expert consensus endorsed shared decision-making for women with severe symptoms. Existing data are too outdated and heterogeneous to apply universally.
Perimenopause Requires a Different Playbook
During perimenopause, estrogen levels surge and crash erratically — standard menopause-dose hormone therapy often does nothing; a low-dose birth control pill is frequently the better tool
The decision to start, continue, or stop hormone therapy should be driven by symptoms and medical history — not arbitrary rules or influencers
Upshot
The fear that followed the WHI left generations of women under-treated and misinformed, and many are still paying the price. Hormone therapy is not right for everyone, but the decision should be driven by symptoms, history, and honest risk-benefit conversation, not by outdated warnings, arbitrary timelines, or wellness culture overcorrections. Women deserve accurate information about their own bodies, and that starts with clinicians who know the evidence and are willing to have a nuanced conversation.
